^
3d
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia (clinicaltrials.gov)
P2, N=92, Recruiting, The First Affiliated Hospital of Soochow University | Trial primary completion date: Sep 2024 --> Sep 2025
Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
3d
Entinostat treatment causes hypophosphatemia and hypocalcemia by increasing Fgf23 in mice. (PubMed, Biochem Biophys Res Commun)
Meanwhile, Entinostat treatment increased the serum level of the active form (intact) Fgf23 and reduced that of Pi and calcium (Ca) as well. This study raised a concern about the anabolic effects of Entinostat in bone, and demonstrated that Entinostat treatment causes hypophosphatemia and hypocalcemia by upregulating Fgf23 mRNA and increasing intact Fgf23 protein in serum.
Preclinical • Journal
|
CTSK (Cathepsin K) • FGF23 (Fibroblast Growth Factor 23) • RUNX2 (RUNX Family Transcription Factor 2)
|
Jingzhuda (entinostat)
4d
Multicomponent syntheses enable the discovery of novel quisinostat-derived chemotypes as histone deacetylase inhibitors. (PubMed, Eur J Med Chem)
Furthermore, these compounds caused hyperacetylation of histone H3 and α-tubulin, indicating robust cellular target engagement. Overall, in this work we have identified the HDAC inhibitor 18b with selective antiplasmodial and 9b, 9d, and 13f with selective anticancer activities, providing valuable hits for further drug development efforts aimed at creating derivatives with reduced cytotoxicity against non-cancer cells compared to quisinostat.
Journal • Epigenetic controller
|
CASP3 (Caspase 3) • HDAC1 (Histone Deacetylase 1) • CASP7 (Caspase 7)
|
quisinostat (JNJ 26481585)
4d
MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov)
P1, N=45, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial primary completion date: Jun 2023 --> Feb 2024
Trial primary completion date
|
CD34 (CD34 molecule)
|
Zolinza (vorinostat) • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim)
4d
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL (clinicaltrials.gov)
P2, N=44, Recruiting, Zhejiang Cancer Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • Epidaza (chidamide) • vindesine
4d
New P1 trial
|
NF1 (Neurofibromin 1)
|
mirdametinib (PD-0325901) • Zolinza (vorinostat)
5d
Discovery of cloxiquine derivatives as potent HDAC inhibitors for the treatment of melanoma via activating PPARγ. (PubMed, Eur J Med Chem)
More importantly, compound CS4 demonstrated significant in vivo anticancer effect compared with SAHA, and exhibited neglectable toxicity. Consequently, CS4 is the potent HDAC inhibitor, which may be developed as the candidate antimelanoma drug.
Journal
|
HDAC1 (Histone Deacetylase 1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
|
Zolinza (vorinostat)
5d
Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment. (PubMed, J Med Chem)
Compound 20c effectively modulated the expression of biomarkers associated with LSD1 and HDAC inhibition and demonstrated superior antiproliferative activity compared to SAHA and 4SC-202 across multiple colorectal cancer cell lines...It demonstrated significantly enhanced antitumor efficacy compared to SAHA, without causing observable toxicity. These findings highlight the potential of LSD1/HDAC dual inhibitors for the treatment of malignant cancers.
Journal
|
HDAC1 (Histone Deacetylase 1)
|
Zolinza (vorinostat) • domatinostat (4SC-202)
5d
Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity. (PubMed, J Med Chem)
Importantly, 10h induced immunogenic cell death (ICD), promoted dendritic cells (DCs) maturation, and activated T cells, thereby initiating antitumor immunity. In conclusion, compound 10h is a novel dual-target ROCK/HDAC inhibitor that represents a promising treatment strategy for TNBC.
Preclinical • Journal
|
HDAC1 (Histone Deacetylase 1)
6d
Comprehensive Analysis of the Prognostic Implications and Biological Function of HDACs in Liver Hepatocellular Carcinoma. (PubMed, Int J Med Sci)
CKD-581 prohibits LIHC progression via inhibiting the cell cycle signaling pathway. CKD-581 holds promise as a therapeutic agent for the clinical management of LIHC.
Journal
|
CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
alteminostat (CKD-581)
6d
Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation. (PubMed, Curr Res Toxicol)
In this study, the four cell lines containing the L861Q mutation were constructed by CRISPR and the anti-tumour effects of CUDC-101 on them were investigated in vitro by various chemosensitivity methods, with afatinib serving as a positive control. The results demonstrated that CUDC-101 inhibited the proliferation and clonogenic capacity on the four cells through the ERK or AKT pathways, decreased the mitochondrial membrane potential of the cells, blocked the cell cycle and promoted apoptosis. Our findings suggest that CUDC-101 may be a promising treatment option for NSCLC patients with the EGFR exon 18 substitution mutation L861Q.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L861Q • EGFR exon 18 mutation
|
Gilotrif (afatinib) • CUDC-101
7d
Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells. (PubMed, Cancers (Basel))
The combination of Panobinostat with Doxorubicin or Etoposide, both of which are used as standard of care in upfront treatment, leads to a synergistic effect in EWS cells. Overall, our data indicate that HDAC2 is overexpressed in many EWS tumor samples and HDAC inhibition is effective in targeting EWS cells, alone and in combination with standard-of-care chemotherapy agents. This work suggests that the addition of an HDAC inhibitor to upfront treatment may improve response.
Journal
|
ALK (Anaplastic lymphoma kinase) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CHEK2 (Checkpoint kinase 2) • JAK1 (Janus Kinase 1) • CHEK1 (Checkpoint kinase 1) • CASP3 (Caspase 3) • HDAC2 (Histone deacetylase 2)
|
CCND1 expression • HDAC2 expression
|
doxorubicin hydrochloride • etoposide IV • Farydak (panobinostat)
7d
Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma. (PubMed, J Exp Clin Cancer Res)
Integrated studies define MYC inhibition by panobinostat as a novel treatment element to be introduced into the therapeutic strategy for patients with metastatic hepatoblastoma.
Journal • Metastases
|
NPM1 (Nucleophosmin 1)
|
cisplatin • doxorubicin hydrochloride • Farydak (panobinostat)
7d
TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas. (PubMed, Neuro Oncol)
TRIM21 may represent a therapeutic target for tumors, and inhibiting TRIM21 could be a potential strategy for tumor treatment.
Journal
|
MAP2K1 (Mitogen-activated protein kinase kinase 1) • TRIM21 (Tripartite Motif Containing 21)
|
fimepinostat (CUDC-907) • quisinostat (JNJ 26481585)
10d
Sincerely20: Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (clinicaltrials.gov)
P2, N=51, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
Trial completion date • Trial primary completion date • IO biomarker • Epigenetic controller
|
PD-L1 expression
|
Tyvyt (sintilimab) • Epidaza (chidamide)
12d
New P2 trial • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK fusion
|
gemcitabine • Epidaza (chidamide) • Ariely (adebrelimab)
12d
New P2 trial • Combination therapy • Metastases
|
Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)
12d
New P2 trial • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
capecitabine • vinorelbine tartrate • Epidaza (chidamide)
12d
Prospective, open-label, phase II clinical study of the combination of Chidamide and Anlotinib ± PD-1/PD-L1 inhibitors in patients with SWI/SNF complex-deficient mutations (ChiCTR2400090522)
P2, N=57, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
New P2 trial • IO biomarker
|
ARID1A (AT-rich interaction domain 1A) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
|
Focus V (anlotinib) • Epidaza (chidamide)
17d
New P2 trial
|
Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • Epidaza (chidamide) • vindesine
17d
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer (clinicaltrials.gov)
P1, N=26, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Talzenna (talazoparib) • Beleodaq (belinostat)
17d
Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function. (PubMed, Sci Rep)
Degradation of STAT3 by C210 enhanced the EBV-reactivating and anticancer capacity of suberoylanilide hydroxamic acid (SAHA). Depletion of XPB blocked SAHA-induced expression of late viral genes and production of infectious virions. These results elucidate a novel Hsp90 inhibitor targeting EBV lytic phase and extend the research on lytic induction strategy, which may offer reference value in the treatment of EBV-positive malignancies.
Journal
|
XBP1 (X-box-binding protein 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
Zolinza (vorinostat)
18d
The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response. (PubMed, Front Pharmacol)
Additionally, NOP58 was linked to drug responses, including Methotrexate, Rapamycin, Sorafenib, and Vorinostat. Its expression level serves as a reliable prognostic biomarker and an actionable therapeutic target, advancing precision medicine for prostate cancer. Targeting NOP58 may enhance therapeutic efficacy and improve outcomes in oncology.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
sorafenib • methotrexate • sirolimus • Zolinza (vorinostat)
18d
Real-world efficacy of chidamide plus R-CHOP in newly diagnosed double-expressor diffuse large B-cell lymphoma. (PubMed, Ther Adv Hematol)
To evaluate the efficacy of a novel histone deacetylase inhibitor, chidamide, in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (CR-CHOP) in the treatment of DEL. The most common grades 3-4 hematologic and nonhematologic toxicity were leukopenia (46.7%) and infection (21%), respectively. This long-term follow-up study indicates that CR-CHOP in untreated DLBCL with the DEL phenotype demonstrates high short-term efficacy and safety as well as promising survival outcomes.
Journal • Real-world evidence • IO biomarker • Real-world effectiveness • Real-world
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
18d
New trial
|
Epidaza (chidamide) • Folotyn (pralatrexate)
18d
Combination of multivalent DR5 receptor clustering agonists and histone deacetylase inhibitors for treatment of colon cancer. (PubMed, J Control Release)
In TRAIL-sensitive colon cancer cells (COLO205, HCT-116), P-cDR5 showed efficacy comparable to anti-DR5 mAb Drozitumab (DRO), but P-cDR5 outperformed DRO in TRAIL-resistant cells (HT-29), highlighting the importance of efficient receptor clustering...Combining P-cDR5 with valproic acid, a histone deacetylase inhibitor, resulted in further enhancement of apoptosis inducing efficacy, along with destabilizing mitochondrial membranes and increased sensitivity of TRAIL-resistant cells. These findings suggest that attaching multiple cDR5 peptides to a flexible water-soluble polymer carrier not only overcomes the limitations of previous designs but also offers a promising avenue for treating resistant cancers, pointing toward the need for further preclinical exploration and validation of this innovative strategy.
Journal • Epigenetic controller
|
TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
|
drozitumab (RG7425)
19d
G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1. (PubMed, Cell Death Dis)
Additionally, the transcriptomes of these cells were reprogrammed to become highly responsive to chemotherapy (cisplatin), targeted therapy (trametinib), and epigenetic therapy (vorinostat). SCARA5 and AOX1 DNA promoters were hypermethylated in NSCLC, and SCARA5 methylation was identified as an epigenetic biomarker in tumors and liquid biopsies from NSCLC patients. Thus, we demonstrate that co-targeting G9a/DNMT1 is a promising strategy to enhance the efficacy of cancer drugs, and SCARA5 methylation could serve as a non-invasive biomarker to monitor tumor progression.
Journal • Tumor cell
|
DNMT1 (DNA methyltransferase 1)
|
DNMT1 expression
|
Mekinist (trametinib) • cisplatin • Zolinza (vorinostat)
19d
Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma. (PubMed, Gut)
Our immunoepigenetic strategy harnesses IFNγ-mediated network to augment the cancer-immunity cycle, revealing a self-reinforcing STAT1-GSDME pyroptotic circuitry as the mechanistic basis for an ongoing phase-II trial to tackle ICB resistance (NCT05873244).
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GZMB (Granzyme B) • HDAC1 (Histone Deacetylase 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • GSDME (Gasdermin E)
|
Keytruda (pembrolizumab) • zabinostat (CXD101)
22d
Chidamide Combined with (+) -JQ-1 to Kill MLL-Rearrangement Acute Myeloid Leukemia Cells by Disrupting the DNA Damage Response Pathway (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Chidamide combined with (+)-JQ-1 can inhibit the proliferation of MLL-r AML cells, inhibit the initiation of protective self-repair of these leukemia cells by inhibiting the DNA damage response pathway, and ultimately increase the apoptosis of these cells, but non- MLL-r AML cells have no similar results.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KMT2A (Lysine Methyltransferase 2A) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • CHEK1 (Checkpoint kinase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • BRD4 (Bromodomain Containing 4) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
MLL rearrangement • MLL rearrangement • BCL2 expression • BAX expression
|
JQ-1 • Epidaza (chidamide)
22d
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=93, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Avastin (bevacizumab) • Loqtorzi (toripalimab-tpzi)
23d
Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Kisqali (ribociclib) • Beleodaq (belinostat)
24d
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=10 --> 23 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
Istodax (romidepsin) • fludarabine IV • busulfan
29d
Chidamide triggers pyroptosis in T-cell lymphoblastic lymphoma/leukemia via the FOXO1/GSDME axis. (PubMed, Chin Med J (Engl))
Our study suggested that chidamide exerts an antitumor effect on T-LBL/ALL and promotes a more inflammatory form of cell death via the FOXO1/GSDME axis, which provides a novel choice of targeted therapy for patients with T-LBL/ALL.
Journal
|
CASP3 (Caspase 3) • FOXO1 (Forkhead box O1) • HDAC2 (Histone deacetylase 2) • HDAC1 (Histone Deacetylase 1) • GSDME (Gasdermin E) • HDAC3 (Histone Deacetylase 3)
|
Epidaza (chidamide)
29d
Enrollment open
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
|
RAS wild-type • EZH2 mutation • EZH2 wild-type
|
Tazverik (tazemetostat) • Beleodaq (belinostat)
30d
Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma. (PubMed, J Exp Clin Cancer Res)
These findings demonstrate that ERAP1 inhibition combined with HDACi entinostat treatment and PD-1 blockade remodels the immune landscape of a non-immunogenic tumor such as NB, making it responsive to checkpoint immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CD4 (CD4 Molecule) • CASP3 (Caspase 3) • ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) • CASP7 (Caspase 7)
|
Jingzhuda (entinostat)
30d
R-ICE+X: Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=76, Recruiting, Ruijin Hospital | Trial primary completion date: Jun 2024 --> Jun 2025
Trial primary completion date
|
carboplatin • Brukinsa (zanubrutinib) • decitabine • Epidaza (chidamide) • pomalidomide • tofacitinib
1m
Approaches for prevention of tumors in patients with rhabdoid tumor predisposition syndrome. (PubMed, Neurooncol Adv)
Potential maintenance regimens may include low-dose traditional chemotherapy or different epigenetic therapies designed to target the epigenetic imbalance that drives RTs. We here review several potential maintenance regimens that may be useful in RTPS.
Review • Journal
|
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
|
Tazverik (tazemetostat) • Farydak (panobinostat)
1m
Development of a prognostic model related to homologous recombination deficiency in glioma based on multiple machine learning. (PubMed, Front Immunol)
Molecular docking highlighted several compounds, notably Panobinostat, as promising for high-risk patients. The prognostic model based on the HRD score threshold and associated genes in glioma offers new insights into the genomic and immunological landscapes, potentially guiding therapeutic strategies. The differential immune profiles associated with HRD-risk groups could inform immunotherapeutic interventions, with our findings paving the way for personalized medicine in glioma treatment.
Journal • IO biomarker • Machine learning
|
HRD (Homologous Recombination Deficiency)
|
HRD • High HRD score
|
Farydak (panobinostat)
1m
New trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
1m
NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target. (PubMed, Int J Biol Sci)
In this study, by conducting bioinformatics analyses as well as in vitro and in vivo experiments, we identified that NUSAP1 was significantly upregulated in LUAD, with a notable correlation with poorer overall survival, higher scores for immunogenicity and immune infiltration, as well as increased sensitivity to conventional chemotherapeutic drugs such as paclitaxel, docetaxel and vinorelbine in LUAD. Furthermore, we identified entinostat as a novel inhibitor of NUSAP1. Pharmacological targeting ERβ/NUSAP1 axis with fulvestrant (ERβ antagonist) or entinostat (novel NUSAP1 inhibitor) significantly reduced LUAD growth both in vitro and in vivo, which may represent effective alternative therapeutic strategies for patients with LUAD.
Journal
|
NUSAP1 (Nucleolar and Spindle Associated Protein 1)
|
NUSAP1 overexpression
|
paclitaxel • docetaxel • fulvestrant • vinorelbine tartrate • Jingzhuda (entinostat)
1m
MEF2C is a Potential Prognostic Biomarker and is Correlated with Immune Infiltrates in Lung Adenocarcinoma. (PubMed, Curr Med Chem)
The results imply that MEF2C could be a valuable indicator for predicting outcomes and a possible target for immunotherapy for LUAD patients.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • MEF2C (Myocyte Enhancer Factor 2C)
|
Tasigna (nilotinib) • irinotecan • topotecan • Farydak (panobinostat)
1m
Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis. (PubMed, Cancer Lett)
Mechanistically, our data point to NRP1 mediating this effect via the down regulation of migration machinery, namely SRC, FAK and ROCK1 expression/activity, that is in part, related to NRP1 interaction with integrin beta 1 (ITGB1). In summary, our data indicate that romidepsin down regulation of NRP1 significantly mitigates the ability of OS cells to seed the lung and establish metastases, and that targeting NRP1 or its effectors with selective inhibitors may be a viable means with which to prevent this deadly aspect of the disease.
Journal • Epigenetic controller
|
NRP1 (Neuropilin 1) • ITGB1 (Integrin Subunit Beta 1) • ROCK1 (Rho Associated Coiled-Coil Containing Protein Kinase 1)
|
Istodax (romidepsin)